Menu
 

Search abstracts


Antitumor activity of cepharanthine and tetrandrine for 2d and 3d culture of breast cancer cells

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: KIYOMI, Anna (Tokyo University of Pharmacy and Life Sciences, Drug Safety and Risk Management)
  • Co-author(s): Anna Kiyomi: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Risako Miyakawa: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Kyosuke Yamazaki: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Juri Matsumoto: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Yuki Nakajima: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Toshihiko Hirano: Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Munetoshi Sugiura: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
  • Abstract:

    Background

    Three-dimensional culture (3D) systems can mimic the in-vivo environment more precisely than 2D culture systems. While tetrandrine (TET), a bis-benzylisoquinoline alkaloid, has been reported for its anti-cancer activity, the effect on breast cancer of cepharanthine (CEP), a TET analog, having a long history of use and little toxicity,..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses